Nancy A. Simonian - 31 Oct 2023 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role: President & CEO, Director
Signature: /s/ Todd Rosenthal, as attorney-in-fact
Issuer symbol: SYRS
Transactions as of: 31 Oct 2023
Net transactions value: -$29,750
Form type: 4
Filing time: 02 Nov 2023, 16:54:12 UTC
Previous filing: 02 Jun 2023
Next filing: 05 Dec 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SYRS	Common Stock	Options Exercise		+40,125	+55%		113,545	31 Oct 2023	Direct	F1
transaction	SYRS	Common Stock	Tax liability	$29,750	-13,401	-12%	$2.22	100,144	01 Nov 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SYRS	Restricted Stock Units	Options Exercise	$0	-40,125	-50%	$0.000000	40,125	31 Oct 2023	Common Stock	40,125		Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock received upon vesting of a restricted stock unit award.
F2	Represents shares used to cover tax withholding on a restricted stock unit release.
F3	Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4	Represents a restricted stock unit award granted on October 6, 2022. These restricted stock units vested as to one half (50%) of the shares on October 31, 2023, and are scheduled to vest as to one half (50%) of the shares on October 31, 2024.